---
title: "Ernexa Therapeutics Inc. (ERNA.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/ERNA.US.md"
symbol: "ERNA.US"
name: "Ernexa Therapeutics Inc."
industry: "Biotechnology"
datetime: "2026-05-19T19:41:15.972Z"
locales:
  - [en](https://longbridge.com/en/quote/ERNA.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ERNA.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ERNA.US.md)
---

# Ernexa Therapeutics Inc. (ERNA.US)

## Company Overview

Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company’s lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.ernexatx.com](https://www.ernexatx.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:12.000Z

**Overall: D (0.66)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 0 / 386 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 0.00% |  |
| Net Profit YoY | 75.27% |  |
| P/B Ratio | 2.08 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 14285668.25 |  |
| Revenue | 0.00 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 87.78% | A |
| Profit Margin | -1834100.00% | E |
| Gross Margin | 0.00% | E |
| Revenue YoY | -99.83% | E |
| Net Profit YoY | 59.16% | B |
| Total Assets YoY | -20.03% | E |
| Net Assets YoY | 107.86% | A |
| Cash Flow Margin | -0.01% | D |
| OCF YoY | -99.83% | E |
| Turnover | 0.00 | E |
| Gearing Ratio | 42.16% | C |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Ernexa Therapeutics Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "0.00%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "75.27%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "2.08",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "14285668.25",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "0.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "87.78%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "-1834100.00%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "0.00%",
          "rating": "E"
        },
        {
          "name": "Revenue YoY",
          "value": "-99.83%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "59.16%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "-20.03%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "107.86%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "-0.01%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "-99.83%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.00",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "42.16%",
          "rating": "C"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -1.25 | 194/386 | - | - | - |
| PB | 2.08 | 190/386 | 2.86 | 2.40 | 2.15 |
| PS (TTM) | 8778.29 | - | 9418.67 | 6651.93 | 21.69 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-08T04:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 1 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 11.03 |
| Highest Target | 30.00 |
| Lowest Target | 30.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/ERNA.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/ERNA.US/norm.md)
- [Related News](https://longbridge.com/en/quote/ERNA.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/ERNA.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**